TY  - DATA
AU  - Selaković, Života
AU  - Soloveva, Veronica
AU  - Gharaibeh, Dima N.
AU  - Wells, Jay
AU  - Šegan, Sandra B.
AU  - Panchal, Rekha G.
AU  - Šolaja, Bogdan A.
PY  - 2015
UR  - https://cherry.chem.bg.ac.rs/handle/123456789/3339
PB  - Amer Chemical Soc, Washington
T2  - ACS INFECTIOUS DISEASES
T1  - Supplementary data for the article: Selaković, Z.; Soloveva, V.; Gharaibeh, D. N.; Wells, J.; Šegan, S.; Panchal, R. G.; Šolaja, B. A. Anti-Ebola Activity of Diazachrysene Small Molecules. ACS Infectious Diseases 2016, 1 (6), 264–271. https://doi.org/10.1021/acsinfecdis.5b00028
UR  - https://hdl.handle.net/21.15107/rcub_cherry_3339
ER  - 

@misc{
author = "Selaković, Života and Soloveva, Veronica and Gharaibeh, Dima N. and Wells, Jay and Šegan, Sandra B. and Panchal, Rekha G. and Šolaja, Bogdan A.",
year = "2015",
publisher = "Amer Chemical Soc, Washington",
journal = "ACS INFECTIOUS DISEASES",
title = "Supplementary data for the article: Selaković, Z.; Soloveva, V.; Gharaibeh, D. N.; Wells, J.; Šegan, S.; Panchal, R. G.; Šolaja, B. A. Anti-Ebola Activity of Diazachrysene Small Molecules. ACS Infectious Diseases 2016, 1 (6), 264–271. https://doi.org/10.1021/acsinfecdis.5b00028",
url = "https://hdl.handle.net/21.15107/rcub_cherry_3339"
}

Selaković, Ž., Soloveva, V., Gharaibeh, D. N., Wells, J., Šegan, S. B., Panchal, R. G.,& Šolaja, B. A.. (2015). Supplementary data for the article: Selaković, Z.; Soloveva, V.; Gharaibeh, D. N.; Wells, J.; Šegan, S.; Panchal, R. G.; Šolaja, B. A. Anti-Ebola Activity of Diazachrysene Small Molecules. ACS Infectious Diseases 2016, 1 (6), 264–271. https://doi.org/10.1021/acsinfecdis.5b00028. in ACS INFECTIOUS DISEASES
Amer Chemical Soc, Washington..
https://hdl.handle.net/21.15107/rcub_cherry_3339

Selaković Ž, Soloveva V, Gharaibeh DN, Wells J, Šegan SB, Panchal RG, Šolaja BA. Supplementary data for the article: Selaković, Z.; Soloveva, V.; Gharaibeh, D. N.; Wells, J.; Šegan, S.; Panchal, R. G.; Šolaja, B. A. Anti-Ebola Activity of Diazachrysene Small Molecules. ACS Infectious Diseases 2016, 1 (6), 264–271. https://doi.org/10.1021/acsinfecdis.5b00028. in ACS INFECTIOUS DISEASES. 2015;.
https://hdl.handle.net/21.15107/rcub_cherry_3339 .

Selaković, Života, Soloveva, Veronica, Gharaibeh, Dima N., Wells, Jay, Šegan, Sandra B., Panchal, Rekha G., Šolaja, Bogdan A., "Supplementary data for the article: Selaković, Z.; Soloveva, V.; Gharaibeh, D. N.; Wells, J.; Šegan, S.; Panchal, R. G.; Šolaja, B. A. Anti-Ebola Activity of Diazachrysene Small Molecules. ACS Infectious Diseases 2016, 1 (6), 264–271. https://doi.org/10.1021/acsinfecdis.5b00028" in ACS INFECTIOUS DISEASES (2015),
https://hdl.handle.net/21.15107/rcub_cherry_3339 .

TY  - JOUR
AU  - Selaković, Života
AU  - Soloveva, Veronica
AU  - Gharaibeh, Dima N.
AU  - Wells, Jay
AU  - Šegan, Sandra B.
AU  - Panchal, Rekha G.
AU  - Šolaja, Bogdan A.
PY  - 2015
UR  - https://cherry.chem.bg.ac.rs/handle/123456789/2035
AB  - Herein we report on a diazachrysene class of small molecules that exhibit potent antiviral activity against the Ebola (EBOV) virus. The antiviral compounds are easily synthesized, and the most active compounds have excellent in vitro activity (0.34-0.70 mu M) and are significantly less lipophilic than their predecessors. The three most potent diazachrysene antivirals do not exhibit any toxicity in vivo and protected 70-90% of the mice at 10 mg/kg following EBOV challenge. Together, these studies suggest that diazachrysenes are a promising class of compounds for hit to lead optimization and as potential Ebola therapeutics.
PB  - Amer Chemical Soc, Washington
T2  - ACS INFECTIOUS DISEASES
T1  - Anti-Ebola Activity of Diazachrysene Small Molecules
VL  - 1
IS  - 6
SP  - 264
EP  - 271
DO  - 10.1021/acsinfecdis.5b00028
ER  - 

@article{
author = "Selaković, Života and Soloveva, Veronica and Gharaibeh, Dima N. and Wells, Jay and Šegan, Sandra B. and Panchal, Rekha G. and Šolaja, Bogdan A.",
year = "2015",
abstract = "Herein we report on a diazachrysene class of small molecules that exhibit potent antiviral activity against the Ebola (EBOV) virus. The antiviral compounds are easily synthesized, and the most active compounds have excellent in vitro activity (0.34-0.70 mu M) and are significantly less lipophilic than their predecessors. The three most potent diazachrysene antivirals do not exhibit any toxicity in vivo and protected 70-90% of the mice at 10 mg/kg following EBOV challenge. Together, these studies suggest that diazachrysenes are a promising class of compounds for hit to lead optimization and as potential Ebola therapeutics.",
publisher = "Amer Chemical Soc, Washington",
journal = "ACS INFECTIOUS DISEASES",
title = "Anti-Ebola Activity of Diazachrysene Small Molecules",
volume = "1",
number = "6",
pages = "264-271",
doi = "10.1021/acsinfecdis.5b00028"
}

Selaković, Ž., Soloveva, V., Gharaibeh, D. N., Wells, J., Šegan, S. B., Panchal, R. G.,& Šolaja, B. A.. (2015). Anti-Ebola Activity of Diazachrysene Small Molecules. in ACS INFECTIOUS DISEASES
Amer Chemical Soc, Washington., 1(6), 264-271.
https://doi.org/10.1021/acsinfecdis.5b00028

Selaković Ž, Soloveva V, Gharaibeh DN, Wells J, Šegan SB, Panchal RG, Šolaja BA. Anti-Ebola Activity of Diazachrysene Small Molecules. in ACS INFECTIOUS DISEASES. 2015;1(6):264-271.
doi:10.1021/acsinfecdis.5b00028 .

Selaković, Života, Soloveva, Veronica, Gharaibeh, Dima N., Wells, Jay, Šegan, Sandra B., Panchal, Rekha G., Šolaja, Bogdan A., "Anti-Ebola Activity of Diazachrysene Small Molecules" in ACS INFECTIOUS DISEASES, 1, no. 6 (2015):264-271,
https://doi.org/10.1021/acsinfecdis.5b00028 . .

TY  - JOUR
AU  - Selaković, Života
AU  - Opsenica, Dejan M.
AU  - Eaton, Brett
AU  - Retterer, Cary
AU  - Bavari, Sina
AU  - Burnett, James C.
AU  - Šolaja, Bogdan A.
AU  - Panchal, Rekha G.
PY  - 2012
UR  - https://cherry.chem.bg.ac.rs/handle/123456789/1528
AB  - Ebola (EBOV) and Marburg (MARV) filoviruses are highly infectious pathogens causing deadly hemorrhagic fever in humans and non-human primates. Promising vaccine candidates providing immunity against filoviruses have been reported. However, the sporadic nature and swift progression of filovirus disease underlines the need for the development of small molecule therapeutics providing immediate antiviral effects. Herein we describe a brief structural exploration of two previously reported diazachrysene (DAAC)-based EBOV inhibitors. Specifically, three analogs were prepared to examine how slight substituent modifications would affect inhibitory efficacy and inhibitor-mediated toxicity during not only EBOV, but also MARV cellular infection. Of the three analogs, one was highly efficacious, providing IC50 values of 0.696 mu M +/- 0.13 mu M and 2.76 mu M +/- 0.21 mu M against EBOV and MARV infection, respectively, with little or no associated cellular toxicity. Overall, the structure-activity and structure-toxicity results from this study provide a framework for the future development of DAAC-based filovirus inhibitors that will be both active and non-toxic in vivo.
PB  - Mdpi Ag, Basel
T2  - Viruses
T1  - A Limited Structural Modification Results in a Significantly More Efficacious Diazachrysene-Based Filovirus Inhibitor
VL  - 4
IS  - 8
SP  - 1279
EP  - 1288
DO  - 10.3390/v4081279
ER  - 

@article{
author = "Selaković, Života and Opsenica, Dejan M. and Eaton, Brett and Retterer, Cary and Bavari, Sina and Burnett, James C. and Šolaja, Bogdan A. and Panchal, Rekha G.",
year = "2012",
abstract = "Ebola (EBOV) and Marburg (MARV) filoviruses are highly infectious pathogens causing deadly hemorrhagic fever in humans and non-human primates. Promising vaccine candidates providing immunity against filoviruses have been reported. However, the sporadic nature and swift progression of filovirus disease underlines the need for the development of small molecule therapeutics providing immediate antiviral effects. Herein we describe a brief structural exploration of two previously reported diazachrysene (DAAC)-based EBOV inhibitors. Specifically, three analogs were prepared to examine how slight substituent modifications would affect inhibitory efficacy and inhibitor-mediated toxicity during not only EBOV, but also MARV cellular infection. Of the three analogs, one was highly efficacious, providing IC50 values of 0.696 mu M +/- 0.13 mu M and 2.76 mu M +/- 0.21 mu M against EBOV and MARV infection, respectively, with little or no associated cellular toxicity. Overall, the structure-activity and structure-toxicity results from this study provide a framework for the future development of DAAC-based filovirus inhibitors that will be both active and non-toxic in vivo.",
publisher = "Mdpi Ag, Basel",
journal = "Viruses",
title = "A Limited Structural Modification Results in a Significantly More Efficacious Diazachrysene-Based Filovirus Inhibitor",
volume = "4",
number = "8",
pages = "1279-1288",
doi = "10.3390/v4081279"
}

Selaković, Ž., Opsenica, D. M., Eaton, B., Retterer, C., Bavari, S., Burnett, J. C., Šolaja, B. A.,& Panchal, R. G.. (2012). A Limited Structural Modification Results in a Significantly More Efficacious Diazachrysene-Based Filovirus Inhibitor. in Viruses
Mdpi Ag, Basel., 4(8), 1279-1288.
https://doi.org/10.3390/v4081279

Selaković Ž, Opsenica DM, Eaton B, Retterer C, Bavari S, Burnett JC, Šolaja BA, Panchal RG. A Limited Structural Modification Results in a Significantly More Efficacious Diazachrysene-Based Filovirus Inhibitor. in Viruses. 2012;4(8):1279-1288.
doi:10.3390/v4081279 .

Selaković, Života, Opsenica, Dejan M., Eaton, Brett, Retterer, Cary, Bavari, Sina, Burnett, James C., Šolaja, Bogdan A., Panchal, Rekha G., "A Limited Structural Modification Results in a Significantly More Efficacious Diazachrysene-Based Filovirus Inhibitor" in Viruses, 4, no. 8 (2012):1279-1288,
https://doi.org/10.3390/v4081279 . .

TY  - DATA
AU  - Opsenica, Igor
AU  - Burnett, James C.
AU  - Gussio, Rick
AU  - Opsenica, Dejan M.
AU  - Todorović, Nina
AU  - Lanteri, Charlotte A.
AU  - Sciotti, Richard J.
AU  - Gettayacamin, Montip
AU  - Basilico, Nicoletta
AU  - Taramelli, Donatella
AU  - Nuss, Jonathan E.
AU  - Wanner, Laura
AU  - Panchal, Rekha G.
AU  - Šolaja, Bogdan A.
AU  - Bavari, Sina
PY  - 2011
UR  - https://cherry.chem.bg.ac.rs/handle/123456789/3569
PB  - Amer Chemical Soc, Washington
T2  - Journal of Medicinal Chemistry
T1  - Supplementary data for article: Opsenica, I.; Burnett, J. C.; Gussio, R.; Opsenica, D. M.; Todorović, N.; Lanteri, C. A.; Sciotti, R. J.; Gettayacamin, M.; Basilico, N.; Taramelli, D.; et al. A Chemotype That Inhibits Three Unrelated Pathogenic Targets: The Botulinum Neurotoxin Serotype A Light Chain, P. Falciparum Malaria, and the Ebola Filovirus. Journal of Medicinal Chemistry 2011, 54 (5), 1157–1169. https://doi.org/10.1021/jm100938u
UR  - https://hdl.handle.net/21.15107/rcub_cherry_3569
ER  - 

@misc{
author = "Opsenica, Igor and Burnett, James C. and Gussio, Rick and Opsenica, Dejan M. and Todorović, Nina and Lanteri, Charlotte A. and Sciotti, Richard J. and Gettayacamin, Montip and Basilico, Nicoletta and Taramelli, Donatella and Nuss, Jonathan E. and Wanner, Laura and Panchal, Rekha G. and Šolaja, Bogdan A. and Bavari, Sina",
year = "2011",
publisher = "Amer Chemical Soc, Washington",
journal = "Journal of Medicinal Chemistry",
title = "Supplementary data for article: Opsenica, I.; Burnett, J. C.; Gussio, R.; Opsenica, D. M.; Todorović, N.; Lanteri, C. A.; Sciotti, R. J.; Gettayacamin, M.; Basilico, N.; Taramelli, D.; et al. A Chemotype That Inhibits Three Unrelated Pathogenic Targets: The Botulinum Neurotoxin Serotype A Light Chain, P. Falciparum Malaria, and the Ebola Filovirus. Journal of Medicinal Chemistry 2011, 54 (5), 1157–1169. https://doi.org/10.1021/jm100938u",
url = "https://hdl.handle.net/21.15107/rcub_cherry_3569"
}

Opsenica, I., Burnett, J. C., Gussio, R., Opsenica, D. M., Todorović, N., Lanteri, C. A., Sciotti, R. J., Gettayacamin, M., Basilico, N., Taramelli, D., Nuss, J. E., Wanner, L., Panchal, R. G., Šolaja, B. A.,& Bavari, S.. (2011). Supplementary data for article: Opsenica, I.; Burnett, J. C.; Gussio, R.; Opsenica, D. M.; Todorović, N.; Lanteri, C. A.; Sciotti, R. J.; Gettayacamin, M.; Basilico, N.; Taramelli, D.; et al. A Chemotype That Inhibits Three Unrelated Pathogenic Targets: The Botulinum Neurotoxin Serotype A Light Chain, P. Falciparum Malaria, and the Ebola Filovirus. Journal of Medicinal Chemistry 2011, 54 (5), 1157–1169. https://doi.org/10.1021/jm100938u. in Journal of Medicinal Chemistry
Amer Chemical Soc, Washington..
https://hdl.handle.net/21.15107/rcub_cherry_3569

Opsenica I, Burnett JC, Gussio R, Opsenica DM, Todorović N, Lanteri CA, Sciotti RJ, Gettayacamin M, Basilico N, Taramelli D, Nuss JE, Wanner L, Panchal RG, Šolaja BA, Bavari S. Supplementary data for article: Opsenica, I.; Burnett, J. C.; Gussio, R.; Opsenica, D. M.; Todorović, N.; Lanteri, C. A.; Sciotti, R. J.; Gettayacamin, M.; Basilico, N.; Taramelli, D.; et al. A Chemotype That Inhibits Three Unrelated Pathogenic Targets: The Botulinum Neurotoxin Serotype A Light Chain, P. Falciparum Malaria, and the Ebola Filovirus. Journal of Medicinal Chemistry 2011, 54 (5), 1157–1169. https://doi.org/10.1021/jm100938u. in Journal of Medicinal Chemistry. 2011;.
https://hdl.handle.net/21.15107/rcub_cherry_3569 .

Opsenica, Igor, Burnett, James C., Gussio, Rick, Opsenica, Dejan M., Todorović, Nina, Lanteri, Charlotte A., Sciotti, Richard J., Gettayacamin, Montip, Basilico, Nicoletta, Taramelli, Donatella, Nuss, Jonathan E., Wanner, Laura, Panchal, Rekha G., Šolaja, Bogdan A., Bavari, Sina, "Supplementary data for article: Opsenica, I.; Burnett, J. C.; Gussio, R.; Opsenica, D. M.; Todorović, N.; Lanteri, C. A.; Sciotti, R. J.; Gettayacamin, M.; Basilico, N.; Taramelli, D.; et al. A Chemotype That Inhibits Three Unrelated Pathogenic Targets: The Botulinum Neurotoxin Serotype A Light Chain, P. Falciparum Malaria, and the Ebola Filovirus. Journal of Medicinal Chemistry 2011, 54 (5), 1157–1169. https://doi.org/10.1021/jm100938u" in Journal of Medicinal Chemistry (2011),
https://hdl.handle.net/21.15107/rcub_cherry_3569 .

TY  - JOUR
AU  - Opsenica, Igor
AU  - Burnett, James C.
AU  - Gussio, Rick
AU  - Opsenica, Dejan M.
AU  - Todorović, Nina
AU  - Lanteri, Charlotte A.
AU  - Sciotti, Richard J.
AU  - Gettayacamin, Montip
AU  - Basilico, Nicoletta
AU  - Taramelli, Donatella
AU  - Nuss, Jonathan E.
AU  - Wanner, Laura
AU  - Panchal, Rekha G.
AU  - Šolaja, Bogdan A.
AU  - Bavari, Sina
PY  - 2011
UR  - https://cherry.chem.bg.ac.rs/handle/123456789/1157
AB  - A 1,7-bis(alkylamino)diazachrysene-based small molecule was previously identified as an inhibitor of the botulinum neurotoxin serotype A light chain metalloprotease. Subsequently, a variety of derivatives of this chemotype were synthesized to develop structure activity relationships, and all are inhibitors of the BoNT/A LC. Three-dimensional analyses indicated that half of the originally discovered 1,7-DAAC structure superimposed well with 4-amino-7-chloroquinolinebased antimalarial agents. This observation led to the discovery that several of the 1,7-DAAC derivatives are potent in vitro inhibitors of Plasmodium falciparum and, in general, are more efficacious against CQ-resistant strains than against CQ-susceptible strains. In addition, by inhibiting beta-hematin formation, the most efficacious 1,7-DAAC-based antimalarials employ a mechanism of action analogous to that of 4,7-ACQ-based antimalarials and are well tolerated by normal cells. One candidate was also effective when administered orally in a rodent-based malaria model. Finally, the 1,7-DAAC-based derivatives were examined for Ebola filovirus inhibition in an assay employing Vero76 cells, and three provided promising antiviral activities and acceptably low toxicities.
PB  - Amer Chemical Soc, Washington
T2  - Journal of Medicinal Chemistry
T1  - A Chemotype That Inhibits Three Unrelated Pathogenic Targets: The Botulinum Neurotoxin Serotype A Light Chain, P. falciparum Malaria, and the Ebola Filovirus
VL  - 54
IS  - 5
SP  - 1157
EP  - 1169
DO  - 10.1021/jm100938u
ER  - 

@article{
author = "Opsenica, Igor and Burnett, James C. and Gussio, Rick and Opsenica, Dejan M. and Todorović, Nina and Lanteri, Charlotte A. and Sciotti, Richard J. and Gettayacamin, Montip and Basilico, Nicoletta and Taramelli, Donatella and Nuss, Jonathan E. and Wanner, Laura and Panchal, Rekha G. and Šolaja, Bogdan A. and Bavari, Sina",
year = "2011",
abstract = "A 1,7-bis(alkylamino)diazachrysene-based small molecule was previously identified as an inhibitor of the botulinum neurotoxin serotype A light chain metalloprotease. Subsequently, a variety of derivatives of this chemotype were synthesized to develop structure activity relationships, and all are inhibitors of the BoNT/A LC. Three-dimensional analyses indicated that half of the originally discovered 1,7-DAAC structure superimposed well with 4-amino-7-chloroquinolinebased antimalarial agents. This observation led to the discovery that several of the 1,7-DAAC derivatives are potent in vitro inhibitors of Plasmodium falciparum and, in general, are more efficacious against CQ-resistant strains than against CQ-susceptible strains. In addition, by inhibiting beta-hematin formation, the most efficacious 1,7-DAAC-based antimalarials employ a mechanism of action analogous to that of 4,7-ACQ-based antimalarials and are well tolerated by normal cells. One candidate was also effective when administered orally in a rodent-based malaria model. Finally, the 1,7-DAAC-based derivatives were examined for Ebola filovirus inhibition in an assay employing Vero76 cells, and three provided promising antiviral activities and acceptably low toxicities.",
publisher = "Amer Chemical Soc, Washington",
journal = "Journal of Medicinal Chemistry",
title = "A Chemotype That Inhibits Three Unrelated Pathogenic Targets: The Botulinum Neurotoxin Serotype A Light Chain, P. falciparum Malaria, and the Ebola Filovirus",
volume = "54",
number = "5",
pages = "1157-1169",
doi = "10.1021/jm100938u"
}

Opsenica, I., Burnett, J. C., Gussio, R., Opsenica, D. M., Todorović, N., Lanteri, C. A., Sciotti, R. J., Gettayacamin, M., Basilico, N., Taramelli, D., Nuss, J. E., Wanner, L., Panchal, R. G., Šolaja, B. A.,& Bavari, S.. (2011). A Chemotype That Inhibits Three Unrelated Pathogenic Targets: The Botulinum Neurotoxin Serotype A Light Chain, P. falciparum Malaria, and the Ebola Filovirus. in Journal of Medicinal Chemistry
Amer Chemical Soc, Washington., 54(5), 1157-1169.
https://doi.org/10.1021/jm100938u

Opsenica I, Burnett JC, Gussio R, Opsenica DM, Todorović N, Lanteri CA, Sciotti RJ, Gettayacamin M, Basilico N, Taramelli D, Nuss JE, Wanner L, Panchal RG, Šolaja BA, Bavari S. A Chemotype That Inhibits Three Unrelated Pathogenic Targets: The Botulinum Neurotoxin Serotype A Light Chain, P. falciparum Malaria, and the Ebola Filovirus. in Journal of Medicinal Chemistry. 2011;54(5):1157-1169.
doi:10.1021/jm100938u .

Opsenica, Igor, Burnett, James C., Gussio, Rick, Opsenica, Dejan M., Todorović, Nina, Lanteri, Charlotte A., Sciotti, Richard J., Gettayacamin, Montip, Basilico, Nicoletta, Taramelli, Donatella, Nuss, Jonathan E., Wanner, Laura, Panchal, Rekha G., Šolaja, Bogdan A., Bavari, Sina, "A Chemotype That Inhibits Three Unrelated Pathogenic Targets: The Botulinum Neurotoxin Serotype A Light Chain, P. falciparum Malaria, and the Ebola Filovirus" in Journal of Medicinal Chemistry, 54, no. 5 (2011):1157-1169,
https://doi.org/10.1021/jm100938u . .

TY  - JOUR
AU  - Burnett, James C.
AU  - Opsenica, Dejan M.
AU  - Sriraghavan, Kamaraj
AU  - Panchal, Rekha G.
AU  - Ruthel, Gordon
AU  - Hermone, Ann R.
AU  - Nguyen, Tam L.
AU  - Kenny, Tara A.
AU  - Lane, Douglas J.
AU  - McGrath, Connor F.
AU  - Schmidt, James J.
AU  - Vennerstrom, Jonathan L.
AU  - Gussio, Rick
AU  - Šolaja, Bogdan A.
AU  - Bavari, Sina
PY  - 2007
UR  - https://cherry.chem.bg.ac.rs/handle/123456789/828
AB  - We previously identified structurally diverse small molecule (non-peptidic) inhibitors (SMNPIs) of the botulinum neurotoxin serotype A (BoNT/A) light chain (LC). Of these, several (including antimalarial drugs) contained a 4-amino-7-chloroquinoline (ACQ) substructure and a separate positive ionizable amine component. The same antimalarials have also been found to interfere with BoNT/A translocation into neurons, via pH elevation of the toxin-mediated endosome. Thus, this structural class of small molecules may serve as dual-function BoNT/A inhibitors. In this study, we used a refined pharmacophore for BoNT/A LC inhibition to identify four new, potent inhibitors of this structural class (IC(50)'s ranged from 3.2 to 17 mu M). Molecular docking indicated that the binding modes for the new SMNPIs are consistent with those of other inhibitors that we have identified, further supporting our structure-based pharmacophore. Finally, structural motifs of the new SMNPIs, as well as two structure-based derivatives, were examined for activity, providing valuable information about pharmacophore component contributions to inhibition.
PB  - Amer Chemical Soc, Washington
T2  - Journal of Medicinal Chemistry
T1  - A refined pharmacophore identifies potent 4-amino-7-chloroquinoline-based inhibitors of the botulinum neurotoxin serotype a metalloprotease
VL  - 50
IS  - 9
SP  - 2127
EP  - 2136
DO  - 10.1021/jm061446e
ER  - 

@article{
author = "Burnett, James C. and Opsenica, Dejan M. and Sriraghavan, Kamaraj and Panchal, Rekha G. and Ruthel, Gordon and Hermone, Ann R. and Nguyen, Tam L. and Kenny, Tara A. and Lane, Douglas J. and McGrath, Connor F. and Schmidt, James J. and Vennerstrom, Jonathan L. and Gussio, Rick and Šolaja, Bogdan A. and Bavari, Sina",
year = "2007",
abstract = "We previously identified structurally diverse small molecule (non-peptidic) inhibitors (SMNPIs) of the botulinum neurotoxin serotype A (BoNT/A) light chain (LC). Of these, several (including antimalarial drugs) contained a 4-amino-7-chloroquinoline (ACQ) substructure and a separate positive ionizable amine component. The same antimalarials have also been found to interfere with BoNT/A translocation into neurons, via pH elevation of the toxin-mediated endosome. Thus, this structural class of small molecules may serve as dual-function BoNT/A inhibitors. In this study, we used a refined pharmacophore for BoNT/A LC inhibition to identify four new, potent inhibitors of this structural class (IC(50)'s ranged from 3.2 to 17 mu M). Molecular docking indicated that the binding modes for the new SMNPIs are consistent with those of other inhibitors that we have identified, further supporting our structure-based pharmacophore. Finally, structural motifs of the new SMNPIs, as well as two structure-based derivatives, were examined for activity, providing valuable information about pharmacophore component contributions to inhibition.",
publisher = "Amer Chemical Soc, Washington",
journal = "Journal of Medicinal Chemistry",
title = "A refined pharmacophore identifies potent 4-amino-7-chloroquinoline-based inhibitors of the botulinum neurotoxin serotype a metalloprotease",
volume = "50",
number = "9",
pages = "2127-2136",
doi = "10.1021/jm061446e"
}

Burnett, J. C., Opsenica, D. M., Sriraghavan, K., Panchal, R. G., Ruthel, G., Hermone, A. R., Nguyen, T. L., Kenny, T. A., Lane, D. J., McGrath, C. F., Schmidt, J. J., Vennerstrom, J. L., Gussio, R., Šolaja, B. A.,& Bavari, S.. (2007). A refined pharmacophore identifies potent 4-amino-7-chloroquinoline-based inhibitors of the botulinum neurotoxin serotype a metalloprotease. in Journal of Medicinal Chemistry
Amer Chemical Soc, Washington., 50(9), 2127-2136.
https://doi.org/10.1021/jm061446e

Burnett JC, Opsenica DM, Sriraghavan K, Panchal RG, Ruthel G, Hermone AR, Nguyen TL, Kenny TA, Lane DJ, McGrath CF, Schmidt JJ, Vennerstrom JL, Gussio R, Šolaja BA, Bavari S. A refined pharmacophore identifies potent 4-amino-7-chloroquinoline-based inhibitors of the botulinum neurotoxin serotype a metalloprotease. in Journal of Medicinal Chemistry. 2007;50(9):2127-2136.
doi:10.1021/jm061446e .

Burnett, James C., Opsenica, Dejan M., Sriraghavan, Kamaraj, Panchal, Rekha G., Ruthel, Gordon, Hermone, Ann R., Nguyen, Tam L., Kenny, Tara A., Lane, Douglas J., McGrath, Connor F., Schmidt, James J., Vennerstrom, Jonathan L., Gussio, Rick, Šolaja, Bogdan A., Bavari, Sina, "A refined pharmacophore identifies potent 4-amino-7-chloroquinoline-based inhibitors of the botulinum neurotoxin serotype a metalloprotease" in Journal of Medicinal Chemistry, 50, no. 9 (2007):2127-2136,
https://doi.org/10.1021/jm061446e . .